Clinical Trial

Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis

Study acronym: PACE-ATTR
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
In cardiac amyloidosis, the heart muscle becomes thick and stiff, making it difficult to pump enough blood with each beat. The heart also often cannot increase its stroke volume, making patients with cardiac amyloidosis more dependent on having an adequate heart rate. Many develop conduction problems and need a pacemaker. In a related condition, heart failure with preserved ejection fraction, setting a higher pacemaker rate improved patients' quality of life. It is not known if the same benefits apply to amyloidosis. This study will test whether raising the pacemaker rate improves well-being and daily function in affected patients.
Trial Details
NCT Number NCT07413081
Lead Sponsor Region Skane
Conditions Cardiac Amyloidosis, Pacemaker
Enrollment 34 participants
Start Date 2026-02-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-17